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Insulin degrading enzyme (IDE) degrades amyloid β (Aβ), which may inhibit the accumulation of Aβ in a brain aﬀected with
dementia of Alzheimer’s type (DAT). A decrease in the activity of IDE results in changes in glucose utilization in the brain, which
could aﬀect the cognitive and psychiatric symptoms of DAT. We investigated a possible association of IDE gene polymorphism
and the behavioral and psychological symptoms of dementia (BPSD) in mild DAT. The genotyping for IDE and apolipoprotein
E (ApoE) was determined in 207 patients with mild DAT and 215 controls. The occurrence of BPSD was demonstrated using the
Behavioral Pathology in Alzheimer’s Disease Rating Scale (BEHAVE-AD). IDE gene polymorphism is unlikely to play a substantial
role in conferring susceptibility to DAT, but it may be involved in the development of aﬀective disturbance through the course
of mild DAT, regardless of the presence of an ApoE ε4 allele. The present data could be the result of a small sample size. Further
investigations using larger samples are thus required to clarify the correlation between IDE gene polymorphism, susceptibility to
DAT, and emergence of BPSD.
Copyright © 2008 Noriko Sato et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Dementia of Alzheimer’s type (DAT) is a progressive degen-
erative disorder in which the behavioral and psychological
symptoms of dementia (BPSD) are unavoidable. These
symptoms constitute a great burden not only on the patients,
but also on their families and caregivers [1]. The stress
levels of caregivers may be reduced by predicting the
occurrence of DAT and the development of DAT-associated
BPSD.
The characteristic causes of neurological pathogenesis
in DAT are amyloid plaque deposition and neuroﬁbrillary
abnormalities in the brain. Amyloid plaque is made up of
amyloid β (Aβ) proteins, which are formed by the prote-
olysis of amyloid precursor protein. Excessive production
and insuﬃcient clearance of Aβ lead to its extracellular
deposition as plaque. One way in which Aβ metabolism can
fail is through hyperinsulinemia, caused by the increase of
insulin resistance through aging, because insulin stimulates
Aβ secretion to the extracellular space. One enzyme that
regulates Aβ is insulin degrading enzyme (IDE) [2–5].
IDE is concentrated in the cytoplasm—and even more so
in the peroxisomes in liver, kidney, muscle, and brain cells—
and it plays a key role in degrading many important peptides
[6–8]. Therefore, not only DAT but also type 2 diabetes
mellitus (DM) are linked to IDE [9, 10] ,a n dD Mi sr e p o r t e d
to promote the incidence of DAT [11].
Other studies have already shown that IDE is linked
to DAT. Neurological investigations have found that the
expression of IDE is reduced in the brains of patients with
DAT [12]. Several genetic linkage studies have discovered the
existence of a susceptibility locus for Alzheimer’s disease on
chromosome 10 [13–15]. The IDE gene, located near the
distal end of linkage region (10q23–q25), is an attractive
candidate for involvement in these phenotypes [16–19].
However, conﬂicting negative results have been reported
[20–26].
Inourstudy,weanalyzedSNPrs1999764,whichislocated
in the intron 1 of the IDE gene and which occurs as the
consequenceofamutationfromthymine(T)tocytosine(C).
We used this SNP because it is more frequently polymorphic
in the Japanese population than other SNPs [23]. This SNP2 Current Gerontology and Geriatrics Research
has not been shown to result in a clear functional change,
but intronic SNP generally caused a change in the expression
of the protein and it aﬀects the quantity and function of the
gene. Therefore, the possible roles of this SNP may lead to
a reduction in IDE activity and could be regarded as genetic
determinantsofpredispositionandthedevelopmentofDAT-
associated psychopathology.
We investigated the relationship between IDE gene
polymorphism and the occurrence of DAT, the development
ofDAT-associatedBPSD,andBPSDinpatientswithsporadic
mildDAT,independentofapolipoproteinE(ApoE)ε4status.
An improved understanding of the relationship between
DAT and IDE gene polymorphism (including the presence
of the ApoE ε4 allele which is considered to be a risk factor
for sporadic DAT) could allow us to predict the occurrence
of DAT and the incidence of BPSD by detecting individual
polymorphisms in the gene for IDE. This would reduce the
burdens on patients, their families, and their caregivers, and




All patients were collected prospectively from outpatients
of the Department of Neuropsychiatry, Hyogo College of
Medicine. Two hundred and seven subjects (73.5 ±8.2y e a r s ,
64 male/143 female) with mild DAT met the NINCDS-
ADRDA criteria for probable Alzheimer’s disease and were
assigned to stage 4 on the functional assessment staging
(FAST) scale [27]. Each patient received a cognitive assess-
ment using the mini-mental state examination (MMSE) at
the time of DAT diagnosis. Functional assessments included
the disability assessment for dementia (DAD), which eval-
uates instrumental and basic activities of daily living [28].
Mean (±standard deviation) duration of follow-up was 2.2±
0.7 years until DAT reached a moderate degree, deﬁned as
FAST stage 5. According to the FAST scale, this duration
of follow-up was consistent with the typical duration of
mild dementia in the clinical progression of DAT [27]. All
patients were receiving donepezil hydrochloride. During the
mild stage of DAT, prevalence of BPSD was determined in
semistructured interviews with the subjects’ caregivers using
the Behavioral Pathology in Alzheimer’s Disease Rating Scale
(BEHAVE-AD) at the time of DAT diagnosis, then checked
onceamonthtoobtaininformationaboutonlythepresence,
not the magnitude, of paranoid and delusional ideation,
hallucinations, activity disturbance, aggressiveness, diurnal
rhythm disturbance, aﬀective disturbance, and anxieties and
phobias. We excluded patients with anyhistory of psychiatric
hospitalizationoruseofmedicationforpsychiatricproblems
atany time beforethe ﬁrst evaluation, aswellas patients with
other forms of dementia such as dementia with Lewy bodies.
TheprevalenceofBPSDwas90DATpatients(43.5%)attime
of diagnosis, but all patients were free of pharmacological
treatment for BPSD. Forty-three patients who were treated
with pharmacological agents for the management of BPSD
duringfollow-upwereexcludedfromthestudy.However,the
Mild DAT patients who received donepezil
hydrochloride MMSE, FAST, DAD, and BEHAVE-AD
assessment in the diagnosis (n = 207)
Monthly FAST and BEHAVE-AD assessments
Patients who ﬁnished the study
164 reached moderate AD
43 received pharmacological treatment for BPSD
Figure 1: Study ﬂow chart. MMSE: Mini-Mental State Exam-
ination; FAST: Functional Assessment Staging; DAD: Disability
Assessment for Dementia; BEHAVE-AD: Behavioral Pathology in
Alzheimer’s Disease Rating Scale.
data taken from these patients before their pharmacological
treatment began were enrolled in the study. The ﬂow chart of
the progress through the study is depicted in Figure 1.
We also collected 215 control subjects (72.1 ± 8.6y e a r s ;
t = 1.672, P = .0953, 85 male/130 female; χ2 = 3.428,
P = .0641) whose age and gender were matched. They were
interviewed to exclude individuals with a history or evidence
of abuse, neurological disease or psychiatric disorders and
recruited from the general community or from among
medical and care staﬀ volunteers in hospitals or health
service facilities. The presence of normal general cognitive
function in these subjects was identiﬁed by a score of greater
than 27 on the MMSE.
These interviews and diagnoses were performed by expe-
rienced psychiatrists who were experts for elderly patients
with cognitive disorders. The patients were followed by the
same psychiatrists.
This study was approved by the ethics committee of
the Hyogo College of Medicine. We gave all subjects, who
were native speakers of Japanese, a suﬃcient explanation for
the purpose of the study and obtained their voluntary and
written informed consent. In the case of DAT, we also gave
this explanation to the legal guardian.
2.2. GenotypingMethod
We took blood from all subjects, injected it into EDTA-
containing tubes, and extracted genomic DNA from those
samples using an Easy DNA kit (TALENT, Trieste, Italy). We
examined IDE genepolymorphism using a polymerase chain
reaction restriction fragment length polymorphism (PCR-
RFLP) method. In other words, we ampliﬁed the target DNA
fragment by PCR, using the primers reported by Boussaha et
al.[21],anddigesteditwithAlw26I(FermentasLifeSciences,
Ontario, Canada) restriction enzyme. The DNA sequences
possessing a T allele were not recognized by Alw26I; those
possessing a C allele were recognized. We also analyzed ApoECurrent Gerontology and Geriatrics Research 3
polymorphism, which has been found to be a serious risk
factor for a sporadic DAT onset [29].
2.3. Statistics
We evaluated the results among the groups by χ2 test for
enumerated data with no ordered relationship, while Stu-
dent’s t-test was used for averaged data. For all comparisons,
values of P < .05 were considered statistically signiﬁcant. In
comparisons between polymorphisms and the evaluation of
eachsymptomaccordingtoBEHAVE-AD,whenweobtained
signiﬁcant results by χ2 testing, we required a stricter
statistical signiﬁcance in accordance with the Bonferroni
correction.
3. Results
3.1. Frequencyof IDE Gene
Polymorphism andAllele
The PCR-RFLP analysis showed that both the DAT and the
controls possessed the T allele more frequently than the C
allele (genotype distribution: χ2 = 3.006, P = .2225, allele
frequency: χ2 = 6.167 × 10
−5, P = .9937). When we ruled
out the DAT patients and controls who carried an ApoE ε4
allele, we got a similar result (genotype distribution: χ2 =
5.397, P = .0673, allele frequency: χ2 = 0.2991, P = .5845).
We concluded that the incidence of DAT had no relevance to
IDE gene polymorphism and allele frequency, regardless of
ApoE ε4 status (see Table 1).
3.2. ExpressionFrequencyof BPSD
In the course of FAST stage 4, 145 DAT patients experi-
enced some BPSD (70.0%). The most frequently observed
symptoms were aﬀective disturbance (32.9%), followed
by anxieties and phobias (26.6%), aggressiveness (24.2%),
paranoid and delusional ideation (20.8%), activity distur-
bance (15.0%), hallucinations (12.6%), and diurnal rhythm
disturbance (10.1%). This observation may diﬀer from the
results obtained by Reisberg et al. [30]. The result indicated
that we gave a referral center consultation service that
received many requests to see subjects with BPSD.
3.3. BPSDExpressionandIDE
GenePolymorphism
Among the patients with BPSD, we compared BPSD expres-
sion and IDE gene polymorphism, but we could not get
signiﬁcance (genotype distribution: χ2 = 3.144, P = .2077,
allele frequency: χ2 = 3.363, P = .0667). We then excluded
the patients who possessed an ApoE ε4 allele, but we still
couldnotgetsigniﬁcance(genotypedistribution:χ2 = 4.056,
P = .1316, allele frequency: χ2 = 3.363, P = .0667). The
presence of an ApoE ε4 allele has been assumed to be
involved in the clinical expression of DAT, including BPSD.
Scarmeas et al. [31] have reported a possible association
between the ApoE ε4 allele and BPSD in DAT patients. We
found that IDE gene polymorphism does not correlate with
the expression of BPSD in patients with or without ApoE ε4.
3.4. Analysisof BEHAVE-ADItems and
IDE GenePolymorphism
We tabulated the analysis of BEHAVE-AD items and IDE
gene polymorphism, which was evaluated during the course
of mild stage of DAT (see Table 2). We analyzed the associa-
tions between IDE gene polymorphism and the presence of
BPSD without the consideration of the magnitude of symp-
toms. We did not investigate the diﬀerence in severity of a
wide variety of BPSD according to IDE gene polymorphism.
After applying the Bonferroni correction, we obtained a
statistically signiﬁcant result pertaining to the aﬀective
disturbance item. The DAT patients who experienced some
aﬀective disturbance tended to have T/C and C/C gene
polymorphism and an increased incidence of the C allele.
Except for those carrying the ApoE ε4 allele, the number of
subjects who exhibited T/C or C/C gene polymorphism or
who possessed the C allele was greater among those patients
with aﬀective disturbance. The tendency toward aﬀective
disturbance among DAT patients possessing the C allele of
the IDE gene was independent of their ApoE ε4 status (see
Table 3). We also compared the T/T gene polymorphism
and C allele among the items of BEHAVE-AD, only aﬀective
disturbance was signiﬁcant with or without ApoE ε4( χ2 =
14.07, P < .001; χ2 = 15.75, P < .001).
3.5. Backgroundand PreparationFactorsof
AffectiveDisturbanceExpression
We set out to determine whether any demographic, disease-
related, or caregiver-related variables could be aﬀecting the
incidence of aﬀective disturbance. We categorized the DAT
patients by presence or absence of aﬀective disturbance,
and we compared several variables across these groups,
beginning with gender (χ2 = 2.588, P = .1077), education
(t = 0.7520, P = .4530), and cognitive function by means
of the MMSE (t = 1.499, P = .1354). Because social and
physical factors such as patient’s environment and caregiver
contribute to the expression of BPSD, we also compared
assessment of ADL (t = 1.627, P = .1053), incidence of
physical complications (χ2 = 2.039, P = .1533) such as
d i a b e t e sm e l l i t u s( χ2 = 0.0990, P = .7527) and hypertension
(χ2 = 0.1040, P = .7471), receipt of social welfare services
(χ2 = 0.0980, P = .7547), age of the patient’s primary
caregiver (t = 1.452, P = .1479), and the primary caregiver’s
relationship to the patient (χ2 = 2.458, P = .4829). But
in none of these cases was there a statistically signiﬁcant
diﬀerence between DAT patients with aﬀective disturbance
and DAT patients without (see Table 4).
4. Discussion
Although we hypothesized that there was a correlation
between IDE gene polymorphism and the susceptibility to
DAT, our study has shown that there is none. There is a4 Current Gerontology and Geriatrics Research
Table 1:GenotypedistributionsandallelefrequenciesofIDEgenepolymorphisminDATpatientsandcontrolsafterstratiﬁcationaccording
to ApoE ε4a l l e l e .
IDE IDE without ApoE ε4
DAT Controls DAT Controls
Gene polymorphism
T/T (%) 136 (65.7) 136 (63.2) 69 (67.0) 113 (65.7)
T/C (%) 62 (30.0) 75 (34.9) 27 (26.2) 56 (32.6)
C/C (%) 9 (4.3) 4 (1.9) 7 (6.8) 3 (1.7)
χ2 value 3.006 5.397
P-value .2225 .0673
Allele frequency
T allele, % 80.7 80.7 80.1 82.0
C allele, % 19.3 19.3 19.9 18.0
χ2 value 6.167 × 10−5 0.2991
P-value .9937 .5845
Table 2: χ2 analysis between IDE genotype and BEHAVE-AD items.
BEHAVE-AD items IDE IDE without ApoE ε4
χ2 P-value χ2 P-value
Paranoid and delusional ideation 0.5681 0.6156
Hallucinations 0.5048 0.9484
Activity disturbance 0.3179 0.4907
Aggressiveness 0.1306 0.3513
Diurnal rhythm disturbance 0.0618 0.0770
Aﬀective disturbance 0.0018∗ 0.0007∗∗
Anxieties and phobias 0.3837 0.2044
∗P = .0126; ∗∗P = .0049 after Bonferroni correction.
correlation, however, between IDE gene polymorphism and
one symptom frequently associated with DAT.
We began by examining earlier studies about any sub-
stantial roles of IDE gene polymorphism in conferring
susceptibility to DAT. One research group has insisted that
there was a correlation between increased risk of DAT
and IDE gene polymorphism in DAT patients without the
ApoE ε4a l l e l e[ 16, 22]. Another report showed that DAT
patients with the particular IDE gene polymorphism and
ApoE ε4alleledevelopedDAT[17],andothersdemonstrated
a relationship between increased risk of DAT and IDE
gene polymorphism that was independent of ApoE ε4a l l e l e
status [18, 19]. Other reports, to the contrary, insisted
that a particular SNP of the IDE gene was not pertinent
to the risk of DAT [20, 21, 23–26] (see Table 5). Our
study could not identify any relationship. The disagreement
among the conclusions of all these authors is probably
due to the fact that diﬀerent authors have examined
diﬀerent SNPs, as well as the fact that the frequency of
gene polymorphism and the distribution of alleles vary
among regions and races. In fact, compared with the
SNP in our study, the Japanese population has a greater
frequency of the C allele in comparison with other races
(NCBI Single Nucleotide Polymorphism Cluster Report: rs
1999764).
Afterreviewingtheliterature,wehypothesizedthatBPSD
expression was aﬀected by IDE gene polymorphism. Because
BPSD is used as a measure of the severity of dementia but
is assessed only at particular times during the evaluation
of DAT, the genetic predisposition could be missed if
BPSD was not being expressed at the time of the patient’s
assessment and assignment to a particular stage of DAT.
Thus a longitudinal study of multiple patients with the same
degree of DAT was necessary.
There is a signiﬁcant discrepancy between the estima-
tions of prevalence of BPSD among patients with DAT in
diﬀerent stages [32]. Other studies have shown that the
frequency of BPSD may reach a peak during the mild or
moderate of the illness and may gradually decrease as the
patient deteriorates intellectually and physically [33–35].
Therefore,weassessedBPSDexpressionamongDATpatients
at same stage. Our association study of BPSD used repeated
measurements across the course of mild DAT. We chose
to study patients diagnosed with mild DAT because it is
comparatively easy to follow up with individual patients
through the whole period of mild dementia and to collect
a large number of patients for a longitudinal study. Our
resultsshowedthatIDEgenepolymorphismhadasigniﬁcant
relevance to BPSD, speciﬁcally to aﬀective disturbance.
Nevertheless, no researcher has investigated this correlationCurrent Gerontology and Geriatrics Research 5
Table 3: Genotype distributions and allele frequencies of IDE gene polymorphism in DAT patients with and without aﬀective disturbance
after stratiﬁcation according to ApoE ε4a l l e l e .














T/T (%) 33 (48.5) 102 (73.4) 15 (41.7) 53 (79.1)
T/C (%) 30 (44.1) 33 (23.7) 17 (47.2) 11 (16.4)
C/C (%) 5 (7.4) 4 (2.9) 4 (11.1) 3 (4.5)
χ2 value 12.66 14.66
P-value .0018∗ .0007∗∗
Allele frequency
T allele, % 70.6 85.3 65.3 87.3
C allele, % 29.4 14.7 34.7 12.7
χ2 value 12.48 14.01
P-value .0004+ .0002++
∗P = .0126; ∗∗P = .0049, +P = .0028; ++P = .0014 after Bonferroni correction.
Table 4:Comparisonofdemographic,disease-related,andcaregiver-relatedvariablesofDATpatientswithandwithoutaﬀectivedisturbance
at the time of diagnosis.
Patients DAT with aﬀective disturbance DAT without aﬀective disturbance
Gender, male/female 16/52 48/91
Education, years 11.8 ±8.11 1 .0 ± 5.8
Mean MMSE score ±SD 19.7 ±3.21 9 .0 ± 3.5
Mean DAD score ±SD 80.0 ±6.97 7 .9 ± 9.6
Physical problems, % 29.4 39.6
Diabetes mellitus, % 7.4 8.6
Hypertension, % 16.2 18.0
Receipt of social welfare services, % 32.4 30.2
Mean caregiver’s age ±SD, years 56.8 ±14.66 0 .2 ±14.9
Relationship, % (spouse/child/daughter-in-law/sibling) (47.1/33.8/16.2/2.9) (56.8/30.9/10.1/2.2)
before us; therefore, we could not compare our results with
others’.
We hypothesized that IDE would have high aﬃnity with
insulin and that its concentration could be regulated by
glucose metabolism. An earlier study found that glucose
metabolism in one part of the cerebral cortex decreased
in DAT patients with BPSD, especially those experiencing
aﬀective disturbance [36]. In addition, glucose utilization
decreases with aging [37]. Moreover, there is a signiﬁcant
interaction between diabetes and depression [38], as well as
between diabetes and neurotransmitters such as serotonin
[39]. This is why only aﬀective disturbance showed a
signiﬁcant link to IDE gene polymorphism. Thus we can
conclude that glucose metabolism and the actions of some
neurotransmitters can aﬀect BPSD expression.
In this study, we tried to make a comparison of some
background and preparation factors such as physical com-
plications, living environment, and caregiver relationship
between the DAT patients with aﬀective disturbance and
those without. However, we could not obtain any clear
results. Although we hypothesized that glucose metabolism
was associated with BPSD expression, the incidence of
diabetes mellitus did not correlation with the incidence of
BPSD. Perhaps this is because blood glucose, which is a
primary energy source for our brain, can be regulated by the
hypothalamic-pituitary-adrenal compensatory system even
if glucose metabolism becomes imbalanced [40]. As stated
above, we could not obtain any signiﬁcant result, but if a
regulated system gradually becomes unwell with aging, the
prevalence of diabetes mellitus can rise.
Genetic, neurobiological, psychological, and social fac-
tors can aﬀect the expression of BPSD, but in our study, we
have concluded that the genetic and neurobiological factors
have the greatest inﬂuence. For example, the possession
of the C allele of the IDE gene can cause patients to
d e v e l o pB P S Ds u c ha sa ﬀective disturbance. This result may
prove that this SNP is in linkage disequilibrium and works
as a functional alteration of IDE, disrupting the balance
of glucose metabolism and neurotransmitter action. These
changes can lead to BPSD expression.6 Current Gerontology and Geriatrics Research
Table 5: Published studies of association between DAT onset and IDE gene polymorphism.
Author (year) No. of DAT No. of control
Association between the risk of
DAT and IDE gene
polymorphism
SNP (NCBI dbs.rs.no.)
Abraham et al. [20] 86 94 No association 3758505, 464953, 4646954,
4646958
Boussaha et al. [21] 202 186 No association 1999764, 1855916
Edland et al. [16];
Edland [22] 80 118 Association among DAT patients
without ApoE ε4 3758505, 4646954, 4646958
Sakai et al. [23] 240 163 No association 1999764, 551266
Bian et al. [17] 210 200 Association among DAT patients
with ApoE ε4 4646953
Nowotny et al. [18] 1217 1257 Association among DAT patients
regardless of ApoE ε4 2251101
Cellini et al. [24] 302 164 No association 3758505, 4646958
Ozturk et al. [25] 1012 771 No association 2251101, 551266, 1832196
Marlowe et al. [26] 179 516 No association
3758505, 4646954, 1832196,
4646958, 1544210




The present data could be the result of small sample size,
small eﬀect size of the polymorphisms, and the resultant
limitation in statistical power. The need for replication using
larger samples might be highlighted. However, previous
studiesinvestigatingIDEpolymorphismsfortheincidenceof
DAT have used subject population of 80 and 1217. Moreover,
positive results in 80 and 210 DAT patients have been
published. Thus the sample size in the present study is not
unusually small (see Table 5), and our ﬁndings should not be
declared spurious on that account.
Throughout this study, we found it diﬃcult to continue
examining the same patients due to their age and medical
condition, and we might not have been able to ﬁnish
the study without the cooperation of patients’ families.
However, being able to predict the expression of certain
peripheral symptoms will enable caregivers to prepare the
necessary care systems and services, and will enable patients
to make the necessary adjustments to their living situations.
Further investigations into the correlation between IDE gene
polymorphism, susceptibility to DAT, and emergence of
BPSD will help even more, so we intend to continue these
studies in the future.
5. Conclusions
IDE gene polymorphism is unlikely to play a substantial role
in conferring susceptibility to DAT, but it may be involved in
the development of aﬀective disturbance through the course
of mild DAT, regardless of the presence of an ApoE ε4a l l e l e .
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